Alerts & Corrections

AHFS Patient Medication Information Update – May 2016

The May update to the AHFS Patient Medication Information (PMI) database has been published. Highlights of the update include:

New PMI Monographs:

  • Amphotericin B Liposomal Injection (AmBisome®)
    • Amphotericin B liposomal injection is used to treat fungal infections such as cryptococcal meningitis and visceral leishmaniasis
  • Dexamethasone Injection (Decadron® & Available generically)
    • Dexamethasone injection is used to treat severe allergic reactions, certain types of edema, gastrointestinal disease, and certain types of arthritis, and other diseases treated by corticosteroids
  • Reslizumab Injection (Cinqair®)
    • Reslizumab injection is used along with other medications to treat asthma

FDA MedWatch Alerts – Monograph Revisions

  • Aripiprazole
    • Warning regarding compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported
  • Ticagrelor and Vortioxetine
    • Brand name change for vortioxetine (Brintellix) due to name confusion with ticagrelor (Brilinta)
  • Olanzapine and Olanzapine injection
    • Rare, but serious skin reactions
  • Fluoroquinolones
    • Serious adverse effects generally outweigh benefits for patients with sinusitis, bronchitis, and uncomplicated UTIs
    • Affected monographs:
      • Ciprofloxacin, ciprofloxacin injection, gemifloxacin, levofloxacin, levofloxacin injection, moxifloxacin, moxifloxacin injection, ofloxacin